

Bay Adelaide Centre - North Tower  
40 Temperance Street, Suite 2700  
Toronto, ON M5H 0B4  
[www.helixbiopharma.com](http://www.helixbiopharma.com)

## **Helix Biopharma Corp. Attends World ADC San Diego**

(Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing novel and unique therapies in the field of immuno-oncology, based on its proprietary technological CEACAM6 platform, DOS47, is pleased to announce that the Company attended the 15th World ADC San Diego from 4–7 November 2024, the world's leading and longest-standing forum on antibody-drug conjugates (ADCs).

World ADC San Diego is a comprehensive forum offering data-driven insights, case study presentations, and informative discussions led by forward-thinking ADC industry pioneers to address the challenges and opportunities of bringing ADCs from bench to bedside. Helix was represented this year by its Medical Adviser, Haematologist-Oncologist and seasoned Pharma executive, Thomas Mehrling, to keep abreast of emerging trends and breakthroughs in the field, as the Company advances its development of L-DOS47, Helix’ first-in-class enzyme-antibody-drug conjugate platform technology.

L-DOS47 is a remarkable ADC in that it specifically binds to an antigen highly expressed on the cells of common, hard-to-treat cancers (CEACAM6, expressed on lung, colon and pancreatic cancer cells) and alkalizes the acidic tumor microenvironment (TME), unleashing the immune system’s anti-tumor defences and enhancing the therapeutic effects of anti-cancer agents.

Helix’ novel approach is currently advancing towards a Phase II study in patients with non-small cell lung cancer (NSCLC), though L-DOS47 is expected to have applications across diverse cancers and in combination with a broad range of anti-cancer agents (chemotherapy, immunotherapies and targeted small molecules), making L-DOS47 a platform technology. Helix is also considering broadening its pipeline with novel ADCs.

Thomas Mehrling, MD, PhD, Medical Adviser, said: “This year’s World ADC San Diego has reaffirmed that ADCs are among most exciting innovations in oncology at the moment, fuelling our conviction that Helix’ first-in-class TME-modifying technology is poised to turn the tables on hard-to-treat, prevalent cancers.”

### **About Helix BioPharma Corp.**

Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer based on our proprietary technological



**November 11, 2024**  
**Press Release**

Bay Adelaide Centre - North Tower  
40 Temperance Street, Suite 2700  
Toronto, ON M5H 0B4  
[www.helixbiopharma.com](http://www.helixbiopharma.com)

platform DOS47. Helix is listed on the TSX under the symbol “HBP”, on OTC PINK under the symbol “HBPCD” and on FWB under the symbol “HBP0”.

**For more information, please contact:**

Helix BioPharma Corp.  
Bay Adelaide Centre - North Tower  
40 Temperance Street, Suite 2700  
Toronto, ON M5H 0B4  
Tel: 604-684-2181  
Jacek Antas, Director  
[jantas@helixbiopharma.com](mailto:jantas@helixbiopharma.com)



## **Forward-Looking Statements and Risks and Uncertainties**

*This news release contains forward-looking statements and information (collectively, “forward looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company’s future business, operations, research and development, including the Company’s activities relating to DOS47. Forward-looking statements can further be identified by the use of forward-looking terminology such as “ongoing”, “estimates”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results.*

*Forward-looking statements are statements about the future and are inherently uncertain and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward- looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management’s current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release.*

*The Company’s actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including without limitation; the risk that the Company’s assumptions may prove to be incorrect; the risk that additional financing may not be obtainable in a timely manner, or at all, and that clinical trials may not commence or complete within anticipated timelines or the anticipated budget or may fail; third party suppliers of necessary services or of drug product and other materials may fail to perform or be unwilling or unable to supply the Company, which could cause delay or cancellation of the Company’s research and development activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to secure necessary strategic partner support; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; and other risks and uncertainties referred to elsewhere in this news release, any of which could cause actual results to vary materially from current results or the Company’s anticipated future results. Certain of these risks and uncertainties, and others affecting the Company, are more fully described in the Company’s annual management’s discussion and analysis for the year ended July 31, 2024 under the heading “Risks and Uncertainties” and Helix’s Annual Information Form, in particular under the headings “Forward-looking Statements” and “Risk Factors”, and other reports filed under the Company’s profile on SEDAR at [www.sedar.com](http://www.sedar.com) from time to time. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix’s management on the date of this new release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.*

---